Yang, J., & Ding, H. (2026). Cost-effectiveness of toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China and the United States healthcare systems. International Journal of Clinical Pharmacy, 48(4), 1533-1548.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Cita Chicago Style (17a ed.)
Yang, Junhao, y Haixia Ding. "Cost-effectiveness of Toripalimab Plus Bevacizumab Versus Sorafenib as First-line Treatment for Advanced Hepatocellular Carcinoma in China and the United States Healthcare Systems."
International Journal of Clinical Pharmacy 48, no. 4 (2026): 1533-1548.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Cita MLA (9a ed.)
Yang, Junhao, y Haixia Ding. "Cost-effectiveness of Toripalimab Plus Bevacizumab Versus Sorafenib as First-line Treatment for Advanced Hepatocellular Carcinoma in China and the United States Healthcare Systems."
International Journal of Clinical Pharmacy, vol. 48, no. 4, 2026, pp. 1533-1548.
Copiado correctamente al portapapeles
Error al copiar al portapapeles
Precaución: Estas citas no son 100% exactas.